Literature DB >> 15259282

Decision-making about hormone replacement therapy by women in England and Scotland.

A Welton1, J Hepworth, N Collins, D Ford, C Knott, S Meredith, A Walgrove, H Wilkes, M Vickers.   

Abstract

OBJECTIVE: The aim of this study was to explore women's decision-making about the balance of risks and benefits of taking hormone replacement therapy (HRT) based on the latest evidence from the Women's Health Initiative (WHI) trial of combined HRT.
METHODS: Women aged 50-69 years, who were eligible for the Women's International Study of long Duration Oestrogen after Menopause (WISDOM) trial, were invited to participate in one of eight focus groups. Participants were asked to discuss their views about taking HRT based on the latest international evidence. RESULTS AND
CONCLUSIONS: Eighty-two women participated overall. Qualitative content analysis was applied to the discussion transcripts. Women regarded the decisions they make about taking HRT as highly personal, and, for women currently taking HRT, the overwhelming reason for continuation was perceived improvement in quality of life regardless of either the risks or the benefits in the longer term.

Entities:  

Mesh:

Year:  2004        PMID: 15259282     DOI: 10.1080/13697130310001651463

Source DB:  PubMed          Journal:  Climacteric        ISSN: 1369-7137            Impact factor:   3.005


  2 in total

1.  Qualitative methods in a randomised controlled trial: the role of an integrated qualitative process evaluation in providing evidence to discontinue the intervention in one arm of a trial of a decision support tool.

Authors:  M J Murtagh; R G Thomson; C R May; T Rapley; B R Heaven; R H Graham; E F Kaner; L Stobbart; M P Eccles
Journal:  Qual Saf Health Care       Date:  2007-06

Review 2.  Knowledge, perceptions and information about hormone therapy (HT) among menopausal women: a systematic review and meta-synthesis.

Authors:  MinFang Tao; YinCheng Teng; HongFang Shao; Ping Wu; Edward J Mills
Journal:  PLoS One       Date:  2011-09-16       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.